Related Experiment Video
Updated: May 10, 2025
Optimization of a Quantitative Micro-neutralization Assay
Published on: December 14, 2016
Four-Color Pseudovirus-Based Neutralization Assay: A Rapid Method for Evaluating Neutralizing Antibodies Against
Fan Gao1,2, Lingjie Xu3, Qian Wang2
1School of Life Sciences, Tianjin University, Tianjin 300072, China.
Background/Objectives:
Enterovirus 71 (EV71) and coxsackieviruses A16 (CA16), A10 (CA10), and A6 (CA6) are the primary pathogens that cause hand, foot, and mouth disease (HFMD). Currently, many manufacturers are developing bivalent, trivalent, and tetravalent vaccines that target these antigens. Cell-based neutralization assay (CBNA), the gold standard for detecting neutralizing antibodies (NtAbs), which are used as indicators of HFMD vaccine efficacy, has several limitations. We aimed to develop a novel assay for detecting NtAbs against a quadrivalent HFMD vaccine.
Methods:
We developed a four-color pseudovirus-based neutralization assay (PBNA), utilizing fluorescent reporter genes, to rapidly evaluate neutralizing antibodies against EV71, CA16, CA10, and CA6 in multivalent vaccines and compared it with CBNA.
Results:
PBNA could rapidly and simultaneously detect NtAbs against the four serotypes and required lesser amounts of sera compared to CBNA. A good consistency in determining NtAb titers was observed for PBNA and CBNA.
Conclusions:
PBNA provides a robust tool for evaluating the efficacy of multivalent HFMD vaccines and conducting seroepidemiological studies.
Insights
A new pseudovirus-based neutralization assay (PBNA) rapidly detects neutralizing antibodies (NtAbs) against four hand, foot, and mouth disease (HFMD) pathogens. This assay offers a consistent and efficient alternative for evaluating HFMD vaccine efficacy.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Enterovirus 71 (EV71), coxsackieviruses A16 (CA16), A10 (CA10), and A6 (CA6) are key causes of hand, foot, and mouth disease (HFMD).
- Development of multivalent vaccines targeting these HFMD pathogens is ongoing.
- Current cell-based neutralization assays (CBNA) for detecting neutralizing antibodies (NtAbs) have limitations.
Purpose of the Study:
- To develop a novel assay for detecting NtAbs against a quadrivalent HFMD vaccine.
- To establish a rapid and efficient method for evaluating HFMD vaccine efficacy.
Main Methods:
- Development of a four-color pseudovirus-based neutralization assay (PBNA).
- Utilized fluorescent reporter genes for detection of NtAbs.
- Compared PBNA performance against the established CBNA.
Main Results:
- PBNA enabled rapid, simultaneous detection of NtAbs against EV71, CA16, CA10, and CA6.
- PBNA required significantly less serum volume compared to CBNA.
- PBNA demonstrated good consistency in determining NtAb titers relative to CBNA.
Conclusions:
- PBNA is a robust tool for evaluating the efficacy of multivalent HFMD vaccines.
- PBNA can be utilized for seroepidemiological studies of HFMD.
- This novel assay offers an improved method for HFMD vaccine assessment.
